Open AccessMepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO
Author(s) -
Ian D. Pavord,
Kenneth R. Chapman,
Mona Bafadhel,
Frank C. Sciurba,
Eric Bradford,
Stephanie Harris,
Bhabita Mayer,
David B. Rubin,
Steven W. Yancey,
Pierluigi Paggiaro
Publication year - 2021
Publication title -
international journal of chronic obstructive pulmonary disease/international journal of copd
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.394
H-Index - 67
eISSN - 1178-2005
pISSN - 1176-9106
DOI - 10.2147/copd.s294333
Subject(s) - medicine , mepolizumab , exacerbation , copd , placebo , clinical endpoint , hazard ratio , eosinophil , randomized controlled trial , confidence interval , pathology , asthma , alternative medicine
A pre-specified meta-analysis of individual patient data from the 52-week METREX and METREO trials, which investigated mepolizumab for chronic obstructive pulmonary disease (COPD) in patients with blood eosinophil counts ≥150 cells/µL (screening) or ≥300 cells/µL (prior year) and frequent exacerbations, enables more robust characterization of mepolizumab efficacy in COPD and exploration of the relationship between blood eosinophil count and treatment responses.